1. |
- Paajanen, L, et al.
(author)
-
Homogenization of milk has no effect on milk-specific antibodies in healthy adults
- 2005
-
In: Milchwissenschaft. - 0026-3788. ; 60:3, s. 239-241
-
Journal article (peer-reviewed)abstract
- It has been claimed that some consumers tolerate unhomogenized cow's milk better than homogenized cow's milk. The aim of this study was to compare the effect of homogenized and unhomogenized milk on the production of specific antibodies against cow's milk proteins (casein, beta-lactoglobulin) and bovine insulin. Thirty-six milk-tolerant volunteers were challenged with homogenized and unhomogenized cow's milk for 28 days in a randomized, open, cross-over study (>400 ml of milk daily). From serum samples taken at baseline and at the end of both milk challenges IgG and IgA were measured by ELISA against casein, beta-lactoglobulin and bovine insulin, and IgE against casein. The antibody production of the subjects remained constant for over 2 months, with no differences between the challenges with homogenized and unhomogenized milk. Inter-individual variation was greater than the intra-individual variation or the variation between the milk challenges. The order of the milk challenges did not affect the results. In conclusion, there seems to be no difference in the immunological responses to homogenized and unhomogenized milk in healthy adults with a good tolerance of milk.
|
|
2. |
- Paajanen, L, et al.
(author)
-
Intestinal cytokine mRNA expression in delayed-type cow's milk allergy
- 2006
-
In: Journal of Pediatric Gastroenterology and Nutrition - JPGN. - : Ovid Technologies (Wolters Kluwer Health). - 0277-2116 .- 1536-4801. ; 43:4, s. 470-476
-
Journal article (peer-reviewed)abstract
- OBJECTIVES: The aim of the study was to investigate the characteristics of intestinal immune activation (ie, a chemokine receptor and cytokine expression profile) in delayed-type cow's milk allergy (CMA) appearing in the form of gastrointestinal symptoms. PATIENTS AND METHODS: In all biopsy samples taken from the duodenum and/or the terminal ileum, 30 were studied for the expression of interferon-gamma, transforming growth factor-beta, chemokine receptor (CCR)-4, CCR-5, IL-2, IL-6, IL-10, IL-12p35, IL-12p40 and IL-18 specific mRNA by real-time quantitative reverse transcriptase-polymerase chain reaction in 26 children ages 3 to 15 years: 10 with untreated delayed-type CMA, 6 with celiac disease (CD) and 10 controls. RESULTS: The children with delayed-type CMA showed lower IL-2 and IL-18 mRNA expression in the duodenum (both P = 0.055) and higher CCR-4 and IL-6 mRNA expression in the terminal ileum (P = 0.055, P = 0.016) compared with the controls. The children with CD exhibited slightly higher expression of interferon-gamma and CCR-4 mRNA (P = 0.054, P = 0.053) and lower expression of IL-18 mRNA (P = 0.004) in the duodenal samples compared with the controls. The mRNA expression levels of regulatory cytokines, transforming growth factor-beta and IL-10 remained similar in all 3 groups. CONCLUSIONS: The children with delayed-type gastrointestinal CMA showed a unique pattern of local intestinal hypersensitivity with Th2 response-related characteristics, a profile differing clearly from the children with CD. © 2006 Lippincott Williams & Wilkins, Inc.
|
|
3. |
- Santoro, Aurelia, et al.
(author)
-
Combating inflammaging through a Mediterranean whole diet approach : The NU-AGE project's conceptual framework and design
- 2014
-
In: Mechanisms of Ageing and Development. - Clare, Ireland : Elsevier BV. - 0047-6374 .- 1872-6216. ; 136-137, s. 3-13
-
Journal article (peer-reviewed)abstract
- The development of a chronic, low grade, inflammatory status named "inflammaging" is a major characteristic of ageing, which plays a critical role in the pathogenesis of age-related diseases. Inflammaging is both local and systemic, and a variety of organs and systems contribute inflammatory stimuli that accumulate lifelong. The NU-AGE rationale is that a one year Mediterranean whole diet (considered by UNESCO a heritage of humanity), newly designed to meet the nutritional needs of the elderly, will reduce inflammaging in fully characterized subjects aged 65-79 years of age, and will have systemic beneficial effects on health status (physical and cognitive). Before and after the dietary intervention a comprehensive set of analyses, including omics (transcriptomics, epigenetics, metabolomics and metagenomics) will be performed to identify the underpinning molecular mechanisms. NU-AGE will set up a comprehensive database as a tool for a systems biology approach to inflammaging and nutrition. NU-AGE is highly interdisciplinary, includes leading research centres in Europe on nutrition and ageing, and is complemented by EU multinational food industries and SMEs, interested in the production of functional and enriched/advanced traditional food tailored for the elderly market, and European Federations targeting policy makers and major stakeholders, from consumers to EU Food & Drink Industries.
|
|